Post Profile






Roche's lung cancer drug wins U.S. approval

(Reuters) - Swiss drugmaker Roche Holding AG's new immunotherapy, Tecentriq, won approval on Tuesday from U.S. health regulators as a second-line lung cancer treatment, a decision seen likely to erode Bristol-Myers Squibb's position in this hotly contested market.
read more

share

Related Posts


A New Credo for Diabetes Health Insurance Coverage Decisions

Diseases & Conditions / Diabetes : Diabetes Mine

Rem Laan became Executive Director of the Sansum Diabetes Research Institute in Santa Barbara, CA, last Spring. Before that, he spent more than 10 years with Roche Diabetes, which he entered via a previous position as Director of Ma...

Roche's Personalized Medicine Zelboraf Receives Positive Opinion From European Authority For The Treatment Of People With BRAF

Health : Medical News Today

Roche (SIX: RO, ROG; OTCQX: RHHBY), announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended that Zelboraf be granted full marketing authorization as a monotherapy for the treatment of adult patients ...

Roche's Trastuzumab Emtansine Has Positive Results Against Metastatic Breast Cancer

Health : Medical News Today

Roche released an announcement today in regards to its phase three trial called EMILIA. The program compared performance of its new drug Trastuzumab Emtansine against standard treatments for HER2-positive Metastatic Breast Cancer th...

Roche lung cancer drug success adds to pressure on Bristol

Health : Reuters: Health

COPENHAGEN (Reuters) - Lung cancer patients on Roche's immune system-boosting drug Tecentriq lived on average 4.2 months longer than those taking chemotherapy in a pivotal study, pressuring Bristol-Myers Squibb's dominant position i...

Comments


Copyright © 2016 Regator, LLC